-EARNINGS RELEASE-

ELRON ELECTRONIC INDUSTRIES ANNOUNCES NET INCOME OF \$47.2 MILLION IN THE SECOND QUARTER OF 2005

Tel Aviv, Israel, August 10, 2005 - Elron Electronic Industries Ltd. (NASDAQ:ELRN) today reported net income for the second quarter of 2005 of \$47.2 million, or \$1.60 per share, compared to \$5.5 million, or \$0.19 per share, in the second quarter of 2004. The net income in the first six months of 2005 amounted to \$42.1 million, or \$1.43 per share, compared to \$9.2 million, or \$0.32 per share, in the first six months of 2004.

The net income Elron reported in the second quarter of 2005 was mainly due to gains resulting from the following events completed in the second quarter of 2005:

- (i) a gain, net of tax, of approximately \$36.0 million resulting from the sale of shares of Partner Communications Company Ltd. (Nasdaq: PTNR) for \$94.0 million;
- (ii) a gain, net of tax, of approximately \$17.2 million resulting from the sale of Elron's holding in Oren Semiconductor for \$20.3 million in cash and Zoran shares; and
- (iii) a gain of approximately \$3.0 million from the decrease in Elron's interest in NetVision following its initial public offering ("IPO") on the Tel-Aviv Stock Exchange.

The above gains were offset mainly by losses, net, which Elron recorded with respect to its group companies in the amount of \$7.4 million and \$12.2 million in the three and six month periods ended June 30, 2005, respectively.

During the first half of 2005 Elron invested approximately \$23 million in new and existing group companies. Investment in new companies in the second quarter of 2005 included \$16.0 million in Teledata, a provider of innovative access products and solutions for both traditional and next generation networks to telecom operators and service providers, and \$1.7 million in NuLens (as part of Elron's total investment of \$2.9 million), a developer of intra-ocular lenses, mainly for cataract and presbyopia procedures.

Liquidity and Shareholders Equity

As of June 30, 2005, Elron's cash, debentures and deposits amounted to approximately \$242.4 million compared with \$175.7 million at December 31, 2004. The increase is mainly due to proceeds received from the sale of Partner shares in the second quarter of 2005 of approximately \$94.0 million.

Shareholders' equity at June 30, 2005, was approximately \$381.6 million, representing approximately 81% of the total assets compared with \$389.1 million representing approximately 78% of total assets at December 31, 2004.

"In the second quarter we completed major exits and an IPO of one of our affiliates which resulted

in significant gains to Elron and we completed two new investments in Teledata and NuLens", said

Doron Birger, Elron's President and CEO. "Our sound financial position enables us to continue

investing in new opportunities, which will establish the foundation for our future growth".

Investors may access Elron's second quarter financial report and a detailed management report on

the company's web site: www.elron.com

Conference call details:

Wednesday, August 10, 2005 10;00 a.m. (EST); 05:00 p.m. Israel

Dial in numbers:

In the US: 1-866 860 9642

In the UK: 0 800 917 5108

In Israel: 03 918 0610

International Participants: +972 3 918 0610

For your convenience, a replay of the call will be available starting two hours after the call ends until

Friday, August 12, 2005. To access the replay please dial **1-866-276-1002** (US),

972-3-925-5942 (Israel) and 0-800-917-4256 (UK).

A replay of the call will also be available for ninety days on the company website.

Elron Electronic Industries Ltd. is high technology holding company based in Israel. Through

affiliates, Elron is engaged with a group of high technology operating companies in the fields of

medical devices, telecom, semiconductors and advanced materials. For further information, visit

http://www.elron.com

Contact:

Tal Raz

Elron Electronic Industries Ltd.

Tel. 972-3-6075555

raz@elron.net

Any statements in this press release that may be considered forward-looking statements are subject to

risks and uncertainties that could cause actual results to differ materially. Actual results may differ

from such forward-looking statements due to the risk factors discussed in periodic reports filed by the

Company with the Securities and Exchange Commission, which the Company urges investors to

consider.

Tables to follow

2

CONDENSED CONSOLIDATED BALANCE SHEETS

In thousands of U.S. Dollars

In thousands of U.S. Dollars	June 30, 2005 Unaudited	December 31, 2004 Audited
ASSETS Total current assets	\$ 273,399	\$ 198,662
INVESTMENTS AND LONG-TERM RECEIVABLES Investments in affiliated companies Investments in other companies and long-term receivables Deferred taxes Severance pay deposits	112,541 58,327 3,957 2,401	117,124 155,929 5,493 2,637
Total long-term assets	177,226	281,183
PROPERTY AND EQUIPMENT, NET	7,925	8,064
INTANGIBLE ASSETS	11,892	13,247
Total assets	\$ 470,442	\$ 501,156
LIABILITIES AND SHAREHOLDERS' EQUITY Total current liabilities	\$ 50,688	\$ 39,845
LONG-TERM LIABILITIES Long-term loans from banks and others Accrued severance pay and retirement obligations Deferred taxes Other	4,200 3,567 7,585	4,072 3,809 41,233 22
Total long-term liabilities	15,352	49,136
MINORITY INTEREST	22,833	23,095
Total Shareholders' Equity	381,569	389,080
Total liabilities and shareholders' equity	\$ 470,442	\$ 501,156

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

In thousands of U.S. Dollars, except share and per share data

	Six months ended		Three months ended			Year ended December				
	June 30,				June 30,		,	31,		
		2005		2004		2005		2004		2004
				Una	udit	ed				Audited
INCOME										
Net revenues Equity in losses of affiliated companies Gain from disposal of businesses and affiliated companies and changes in holdings in affiliated	\$	8,518 (7,827)	\$	7,001 (2,098)	\$	(4,244)	\$	3,576 (1,709)	\$	16,330 (10,492)
companies, net		22,389		27,901		22,399		21,821		132,396
Other income, net		56,548		4,187		56,262		1,750		4,784
		79,628		36,991		78,677		25,438		143,018
COSTS AND EXPENSES		12,299		15,385		5,886		6,856		39,164
Income before taxes on income		67,329		21,606		72,791		18,582		103,854
Taxes on income	(25,887)		(8,154)		(26,042)		(7,512)		(15,132)
Income from continuing operations after taxes on income Minority interest in losses (income) of		41,442		13,452		46,749		11,070		88,722
subsidiaries		645		(3,895)		451		(5,535)		(4,135)
Income from continuing operations		42,087		9,557		47,200		5,535		84,587
Loss from discontinued operations		-		(356)				(56)		(454)
Net income	\$	42,087	\$	9,201	\$	47,200	\$	5,479	\$	84,133
Basic Income per share	\$	1.43	\$	0.32	\$	1.60	\$	0.19	\$	2.87
Diluted income per share	\$	1.42	\$	0.31	\$	1.60	\$	0.19	\$	2.86
Weighted average number of ordinary shares used in computing basic net income per share (thousands) Weighted average number of ordinary shares used in computing diluted net		29,415		29,211	_	29,416		29,212		29,266
income per share (thousands)	_	29,543	_	29,323	_	29,538		29,340		29,385

MANAGEMENT REPORT FOR THE SECOND QUARTER ENDED JUNE 30, 2005

The following management report should be read in conjunction with our Condensed Interim Consolidated Financial Statements as of June 30, 2005 and notes thereto and with our Annual Consolidated Financial Statements as of December 31, 2004 and notes thereto, filed with the Securities and Exchange Commission under item 18 to our annual report on Form 20-F for the year ended December 31, 2004 ("2004 20-F"). This report contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements may be identified by the words "anticipate", "believe", "estimate", "expect", "plan" and similar expressions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those discussed in our filings with the Securities and Exchange Commission from time to time.

OVERVIEW

We are a high technology operational holding company that operates through subsidiaries and affiliated companies, referred to as our group companies. Founded in 1962, we have been a major force in the development of the Israeli high technology industry by building Israeli and Israel-related companies with technologies in the fields of medical devices, advanced defense electronics, telecom, semiconductors, software products and services and advanced materials. Historically, most of our group companies were established together with entrepreneurs or started as activities within Elron and were subsequently spun-off.

In addition, some of our group companies grew out of our subsidiary, RDC-Rafael Development Corporation Ltd. ("RDC"), established with Rafael, the largest research and development organization of Israel's Ministry of Defense. RDC was established pursuant to an agreement entered into in July 1993 for the purposes of exploiting Rafael's technology in non-military markets. RDC has first rights to commercially exploit technologies of Rafael in non-military markets, which rights are dependent primarily upon RDC's identification of new and existing military technology developed by Rafael.

Our group companies include both publicly traded and privately held companies.

Our activities range from complete operational control over the business to involvement in the management of our group companies in which we maintain controlling or significant holdings, and, in a limited number of cases, non-significant holdings. We participate in the management of most of our group companies by means of active membership on their boards of directors and board committees. As a result, we are involved in matters of policy, strategic planning, marketing, selecting and manning senior management positions, approving investments and budgets, financing and the overall ongoing monitoring of our group companies' performance. In addition to our representation on the boards of directors of our group companies, we provide hands-on assistance to the group companies' management in support of their growth. We view our hands-on involvement in the operations of our group companies as a key element of our business. Our group companies therefore benefit from the experience of our management team in various areas in which they need support and leadership, including, but not limited to, strategic planning, research and development guidance, identifying joint venture opportunities, introductions to potential customers and investors, risk management, market analysis, business plan preparation, budgetary control, and legal support.

Technology industries are characterized by the high degree of risk inherent in their products, their continuous technological innovation and their penetration into world markets, which requires investment of considerable resources and continuous development efforts. The future success of our group companies is dependent upon their technological quality, prices and nature of their products in comparison to their competitors and their ability to introduce new products to the markets at the right time, while offering cost effective solutions suitable to their customers' needs as well as their ability to raise financing and the condition of the capital markets.

We expect to continue to build and realize value for our shareholders through the sale to third parties of a portion or all of our holdings in, or the issuance of shares by, our group companies, while simultaneously pursuing the acquisition of, or investment in, new and existing companies at different stages of development including early stage and more mature companies. We believe that this strategy provides the ability to increase shareholder value as well as to create capital to support the growth of our group companies and to invest in new opportunities. The nature of our business, therefore, will result in some volatility in our results of operations, depending on the transactions that occur within a particular period.

Our net income (or loss) in any given period is due, for the most part, to the results of operations of our group companies (which are accounted by us under the consolidation or equity method of accounting) and dispositions and changes in our holdings of group companies. As most of our group companies are technology companies which have not yet generated significant revenues and which invest considerable resources in research and development and in marketing activities, we have experienced, and expect to continue to experience, losses in respect of these companies. However, as a result of new accounting pronouncements described below under "CRITICAL ACCOUNTING POLICIES", some of our group companies and new companies in which we may invest may be accounted for at cost, thereby not affecting our results of operation. We anticipate this change may have a significant effect on our results of operations.

Our capital resources in any given period are primarily affected by the extent of our investment in existing and new companies and the realization of certain holdings. The results of operations of our group companies, and consequently, our results of operations and capital resources, are affected by general economic conditions as well as by factors specifically related to the technology markets, which also affect the ability of our group companies to raise financing and our ability to dispose of holdings and realize gains from our holdings.

TREND INFORMATION

Technology industries are affected by economic trends and the condition of the capital markets. Since the second half of 2003, there has been a recovery in the technology sectors and capital markets from the downturn which commenced in 2001. This trend was reflected in the improvement in the results of operations of most of our group companies as well as the raising of funds from new strategic and other investors in private placements completed by some of our group companies. In addition, we recorded significant gains from realizing certain of our holdings, mainly in 2004 as a result of the sale of our holdings in Elbit Systems Ltd. (Nasdaq: ESLT) ("Elbit Systems"), and in the second quarter of 2005 from the sale of most of our shares in Partner Communications Company Ltd. (Nasdaq: PTNR) ("Partner") and the sale of all of our shares in Oren Semiconductor, Inc. ("Oren") (see below under "RECENT DEVELOPMENTS"). Should the improvement in the technology sectors and capital markets continue, we anticipate that it will have a positive effect on our group companies and their ability to raise additional capital.

We also anticipate increasing our investments in new companies in our main areas of operation, and we are currently considering investments in new companies in different stages of their life cycle including early stage and more mature companies. In this regard, new companies in which we invested in 2004 and in 2005 to date include a \$6.7 million investment in Jordan Valley Semiconductors Ltd. ("Jordan Valley"), operating in the field of semiconductors, a \$3.0 million investment in Starling Advanced Communications Ltd. ("Starling"), operating in the field of broadband communication, a \$16 million investment in Teledata Networks Ltd. ("Teledata"), a telecommunications company, and two investments in medical device companies, namely, a \$7.3 million investment in Impliant, Inc. ("Impliant"), and a \$1.7 million investment in NuLens Ltd. ("NuLens") (see below under "RECENT DEVELOPMENTS").

RECENT DEVELOPMENTS

Sale of a majority of our holdings in Partner. On April 20, 2005, we completed the sale of 12,765,190 shares of Partner held by us, to Partner, for approximately \$94.0 million, as part of the sale together with the other Israeli founding shareholders of Partner, of an aggregate of 33,317,933 Partner shares to Partner for aggregate consideration of approximately \$245 million. As a result, we recorded in the second quarter of 2005 a gain, net of tax, of approximately \$36.0 million. Following the sale, we continue to hold 3,091,361 shares of Partner, representing approximately 2% of Partner's outstanding shares, almost all of which are subject to transfer restrictions under Partner's Israeli communications license but are no longer pledged to secure debt of Partner.

Investment in NuLens. On April 21, 2005, we invested approximately \$1.7 million investment in NuLens, an Israeli medical device company operating in the field of intra-ocular lenses, mainly for cataract and presbyopia procedures. The investment is the first of two installments, of which the second of approximately \$1.2 million is scheduled after NuLens achieves a certain milestone. The total investment of \$2.9 million is part of an aggregate investment of approximately \$3.4 million, following which Elron will hold 25% of NuLens on a fully diluted basis, if and when the milestone is achieved.

Investment in Teledata. On May 8, 2005, we completed a new investment of \$16 million in Teledata. The investment was part of an aggregate round of financing of \$19 million in which FBR Infinity II Ventures ("Infinity"), a related venture capital fund, invested \$3 million. Following the investment, we hold approximately 21% of Teledata and Infinity holds approximately 4% of Teledata, each on a fully diluted basis. We and Infinity entered into a voting agreement with respect to our holdings in Teledata. Teledata provides innovative access products and solutions for both traditional and next generation networks to telecom operators and service providers.

NetVision Initial Public Offering. On May 19, 2005, NetVision Ltd. ("NetVision") completed its initial public offering on the Tel Aviv Stock Exchange, or TASE, in Israel of shares and convertible securities in consideration for aggregate immediate net proceeds of approximately NIS135 million (approximately \$31 million). In addition, future proceeds from the exercise of options sold in the offering may amount up to approximately NIS28.8 million (approximately \$6.6 million). Discount Investment Corporation Ltd. ("DIC"), which currently holds approximately 48% of our shares, is the other major shareholder of NetVision. We and DIC each converted approximately \$3.1 million of loans into equity of NetVision immediately prior to the offering and \$2.2 million in loans was repaid to each of us from the proceeds of the offering. As a result of the initial public offering, our holding in NetVision decreased from 45.7% to approximately 39% (27.4% on a fully diluted basis taking into account the possible exercise of the convertible securities) resulting in a gain for Elron in the second quarter of 2005 of approximately \$3.0 million.

Sale of holdings in Oren. On June 10, 2005, Zoran Corporation, or Zoran (Nasdaq: ZRAN), completed the acquisition of Oren in which we held a 41% interest. From the proceeds of the acquisition, we received cash of approximately \$12.5 million (of which approximately \$2.0 million is held in escrow under the terms of the agreement) and 613,410 Zoran shares with a market value of approximately \$7.7 million based on Zoran's share price on the completion date of the acquisition. As a result of the transaction, we recorded a gain in the second quarter of 2005, net of tax, of approximately \$17.2 million. As of June 30, 2005, the common shares

held by us constituted approximately 1% of the outstanding share capital of Zoran and were accounted for as available for sale securities in accordance with SFAS 115 "Accounting for Certain Investments in Debt and Equity Securities". During July 2005 we sold all our shares of Zoran for \$8.8 million, resulting in a gain, net of tax, to be recorded in the third quarter of 2005 of \$0.7 million.

CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS

Concurrently with the announcement of the sale of our shares in Elbit Systems in 2004, we announced that, as a result of the transaction, we may be characterized as a "passive foreign investment company" (PFIC) for U.S. federal income tax purposes for 2004. This would result in adverse tax consequences for our U.S. shareholders, but not for Elron. At the time we filed our Form 6-K with the Securities and Exchange Commission regarding this matter, however, we believed, and our tax advisors concurred, that for 2004 we could potentially rely on the "change of business" exception to PFIC status provided under Section 1298(b)(3) of the U.S. Internal Revenue Code of 1986, as amended. Pursuant to this exception, in order to avoid PFIC status in 2004, we cannot be a PFIC in 2005 and 2006 (which cannot be determined at this time) or in any year prior to 2004 (which we believe was not the case). The tests for determining PFIC status are impacted, among others, by changes in our holdings and in the value of our group companies which are difficult to predict. Moreover, the sale of our shares in Partner in 2005, as described above, generated significant passive income. As a result, we believe that it is reasonably possible that we will be treated as a PFIC in 2005 and, as a result, in 2004 as well. The ultimate determination of our PFIC status for 2005 will depend on the composition of our gross income and assets for the entire year, the values of those assets, which are difficult to predict at this time and the appropriate value of our ownership interest in our group companies. Therefore, it is unclear whether the "change of business" exception would ultimately be satisfied for 2004.

CRITICAL ACCOUNTING POLICIES

We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States ("US GAAP"). Our significant accounting policies are more fully described in Note 2 of the Notes to our 2004 Annual Consolidated Financial Statements. The accounting policies which are particularly important to the assessment of our financial position and results of operations are described under item 5 to our 2004 20-F under "Critical Accounting Policies".

As more fully described in our management report for the year ended December 31, 2004, during 2004 the Emerging Issues Task Force of the Financial Accounting Standards Board ("EITF") reached a consensus on Issue No. 02-14, "Whether an Investor Should Apply the Equity Method of Accounting to Investments Other Than Common Stock" ("EITF 02-14"), according to which the equity method of accounting should be applied to investments in common stock and in in-substance common stock if the investor has the ability to exercise significant influence over the operating and financial policies of the investee. EITF 02-14 defines in-substance common stock as an investment with similar risk and reward characteristics to common stock. The provisions of EITF 02-14 were effective beginning in the fourth quarter of 2004. In certain holdings we invested, among others, in preferred shares which include rights, among others, such as cumulative dividends, participating rights, dividend preferences and liquidation preferences. Upon adoption of EITF 02-14, we evaluated the impact of its provisions and found that there were no investments that were previously accounted for by the equity method which were not considered to be in-substance common stock, nor were there investments that were in-substance common stock that were not accounted for under the equity method of accounting prior to the effective date of EITF 02-14 and which should be accounted as such in accordance with EITF 02-14. However, new companies in which we invested since the fourth quarter of 2004, namely Jordan Valley, Impliant and Teledata, are accounted for at cost notwithstanding our significant influence in such companies, as the investment in these companies is not considered to be insubstance common stock. Any assessment of whether we hold in-substance common stock in a group company is judgmental in nature and involves the use of significant estimates and assumptions such as assessing the fair value of the subordinated equity of the group company.

BASIS OF PRESENTATION

Consolidation. Our consolidated financial statements include the accounts of Elron and all of our direct or indirect (through Elbit and DEP) controlled subsidiaries. The following are our main subsidiaries:

Three and Six months ended June 30,					
	2005			2004	
Elron TeleSoft RDC Galil Medical	SELA ² MediaGate	3DV Starling	Elron TeleSoft RDC Galil Medical	MediaGate 3DV Starling	ESW ¹

¹ Elron SW, Inc. ("ESW"), formerly Elron Software. ESW was liquidated as of December 31, 2004.

Equity Method. Our main group companies held by us or through Elbit, DEP, Galil Medical and/or RDC accounted for under the equity method of accounting include:

² Semiconductor Engineering Laboratories Ltd.("SELA") has been consolidated since the end of the second quarter of 2004.

Three and Six months ended June 30,

	2005			2004	
Given Imaging	ChipX	Oncura	Elbit Systems ¹	ChipX	Oncura
Oren Semiconductor ²	Wavion	Pulsicom	Given Imaging	Wavion	Pulsicom
NetVision	Notal Vision	NuLens	Oren Semiconductor	Notal Vision	CellAct
	AMT	CellAct	NetVision	AMT	$SELA^3$

¹ Sold on July 28, 2004.

RESULTS OF OPERATIONS

Three and six months ended June 30, 2005 compared to three and six months Ended June 30, 2004.

The following tables set forth our results of operations in the reported period:

	Three months end	ded June 30,	Six months ended June 30,				
	2005	2004	2005	2004			
		(millions of \$, except per share data)					
Net income	47.2	5.5	42.1	9.2			
Net income per share	1.60	0.19	1.43	0.32			

The net income we reported in the second quarter of 2005 was mainly due to the following gains from changes in holding and dispositions of group companies:

- (i) a gain, net of tax, of approximately \$36.0 million resulting from the sale of Partner's shares in consideration for \$94.0 million;
- (ii) a gain, net of tax, of approximately \$17.2 million resulting from the sale of Oren's shares in consideration for \$20.3 million in cash and Zoran shares; and
- (iii) a gain of approximately \$3.0 million from the decrease in our interest in NetVision following its initial public offering. No gains from changes in holding and dispositions of group companies were recorded in the first quarter of 2005.

The above gains were offset by losses, net, which we recorded with respect to our group companies in the amount of \$7.4 million and \$12.2 million in the three and six month periods ended June 30, 2005, respectively.

The net income we reported in the six months ended June 30, 2004 included the following gains from changes in holding and dispositions of group companies:

- (i) a gain, net of tax and minority interest, of approximately \$6.7 million resulting from of the sale of Given Imaging's shares by RDC and the decrease in our direct and indirect interest in Given Imaging following the completion of Given Imaging's secondary public offering in the second quarter of 2004;
- (ii) a gain of approximately \$5.3 million resulting from the sale in the first quarter of 2004 of our shares in KIT eLearning; and
- (iii) a gain, net of tax, of approximately \$3.3 million resulting from the sale of Zix Corporation shares in consideration for \$7.0 million.

The above gains were offset by losses, net, which we recorded with respect to our group companies in the amount of \$2.4 million and \$4.1 million in the three and six month periods ended June 30, 2004, respectively.

Reportable Segments

Our reportable segments are: i) The Systems and Projects Segment - Elron TeleSoft; and ii) Other Holdings and The Corporate Operations, which includes our holdings in subsidiaries, affiliates and other companies, engaged in various fields of advanced technology, and corporate operations, which provides strategic and operational support to the group companies. Prior to September 2, 2003, we operated through ESW in a third business segment – Internet Products – which has been reclassified as discontinued operations. ESW was voluntarily dissolved as of December 31, 2004, following the sale of all of its assets in 2003 to Zix Corporation.

At June 30, 2005, our main group companies were classified into the following segments:

	Systems and projects	Other holdings and corporate operations
Consolidated	Elron TeleSoft	RDC; Galil Medical; 3DV; Starling; SELA.
Equity basis		Given Imaging; Oncura; NetVision; ChipX; Notal Vision; Wavion; AMT; Pulsicom; NuLens, CellAct.
Cost		Jordan Valley; Impliant; Teledata.
Available-for-sale Securities		Partner, Elbit Vision Systems, Zoran.

² Sold on June 10, 2005.

³ SELA has been consolidated since the end of the second quarter of 2004.

The following tables reflect our consolidated data by reported segments:

	Elron	Other holdings and corporate	Discontinued operations of		
	Telesoft	operations	ESW	Consolidated	
			ons of \$)		
		Three months end	led June 30, 2005		
Income*	1.0	77.7	-	78.7	
Costs and Expenses	2.6	3.3	-	5.9	
Income (loss) from continuing operations	(1.6)	48.8	-	47.2	
Net income (loss)	(1.6)	48.8	-	47.2	
	Three months ended June 30, 2004				
Income*	1.8	23.6	-	25.4	
Costs and Expenses	2.4	4.5	-	6.9	
Income (loss) from continuing operations	(0.6)	6.1	-	5.5	
Net income (loss)	(0.6)	6.1	-	5.5	
		Six months ende	ed June 30, 2005		
Income*	2.3	77.3	-	79.6	
Costs and Expenses	4.3	8.0	-	12.3	
Income (loss) from continuing operations	(2.0)	44.1	-	42.1	
Net income (loss)	(2.0)	44.1	-	42.1	
		Six months ende	ed June 30, 2004		
Income*	3.4	33.6	-	37.0	
Costs and Expenses	4.5	10.9	-	15.4	
Income (loss) from continuing operations	(1.1)	10.7	-	9.6	
Loss from discontinued operations	-	-	(0.4)	(0.4)	
Net income(loss)	(1.1)	10.7	(0.4)	9.2	

Systems and Projects - Elron TeleSoft

Elron TeleSoft is focused on telecom network management products and services. The following table sets forth the operating results of Elron TeleSoft:

	Three months er	nded June 30,	Six months ende	ed June 30,
·	2005	2004	2005	2004
-		(millions	of \$)	
Net revenues	1.0	1.8	2.3	3.4
Cost of revenues	<u>0.5</u>	<u>1.3</u>	<u>1.3</u>	<u>2.2</u>
Gross profit	0.5	0.5	1.0	1.2
Operating expenses*	0.9	0.7	1.9	1.4
Amortization of other assets	-	0.2	-	0.4
Impairment of goodwill	(1.3)	<u>=</u>	<u>(1.3)</u>	Ξ
Operating loss	(1.7)	(0.4)	(2.2)	(0.6)
Finance income (expenses), net	<u>0.1</u>	<u>(0.2)</u>	<u>0.2</u>	<u>(0.5)</u>
Net loss	(1.6)	<u>(0.6)</u>	(2.0)	(1.1)

^{*}Excluding amortization of other assets and impairment of goodwill, which are presented separately.

Revenues. Elron TeleSoft's net revenues decreased by \$0.8 million and \$1.1 million, or 44% and 32%, to \$1.0 million and \$2.3 million in the three and six month periods ended June 30, 2005, compared to \$1.8 million and \$3.4 million for the same periods of 2004. The decrease resulted mainly from the decrease in projects revenues and in revenues derived from sale of third parties' products, as a result of Elron TeleSoft's efforts to focus on revenue assurance products.

Cost of revenues. Cost of revenues of Elron TeleSoft in the three and six month periods ended June 30, 2005 were \$0.5 million and \$1.3 million, representing a gross margin of approximately 50% and 44%, compared to \$1.3 million and \$2.2 million in the three and six month periods ended June 30, 2004, representing a gross margin of 28% and 35%. The increase in gross margin was due to changes in the revenue mix as license revenues with high gross margin increased relative to revenues derived from projects and sale of third party products, which have lower gross margin.

^{*} Income in the other holdings and corporate operations includes net losses from equity investments.

Operating expenses (excluding amortization of other assets and impairment of goodwill which are presented separately) increased to \$0.9 million and \$1.9 million in the three and six month periods ended June 30, 2005, compared to \$0.7 million and \$1.4 million in the comparable periods in 2004, resulting from the increase in development expenses of the company's new revenue assurance line of products and an increase in sales and marketing expenses associated with launching these products in the international market.

Impairment of goodwill. In light of Elron TeleSoft's results of operations, Elron Telesoft tested its goodwill for impairment, resulting in an impairment loss of \$1.3 million in the second quarter of 2005.

Operating loss. As a result of all the above, Elron TeleSoft's operating loss amounted to \$1.7 million and \$2.2 million in the three and six month periods ended June 30, 2005, compared to \$0.4 million and \$0.6 million for the same periods of 2004.

Finance income (expense), net. Finance income in the three and six month periods ended June 30, 2005 amounted to \$0.1 million and \$0.2 million compared to finance expenses of \$0.2 million and \$0.5 million in the same periods in 2004, primarily as a result of the repayment of the majority of Elron Telesoft's bank loans (financed by an investment by us) and translation gains resulting from the devaluation of the New Israeli Shekel (NIS) against the US Dollar.

The ability of Elron TeleSoft to increase its revenues and improve its operating results in the near future is dependent upon general economic conditions and, in particular, on an increase in telecom capital expenditure, as well as its ability to penetrate the international market and whether its efforts to bring enhanced and new products to market are successful.

Other Holdings and the Corporate Operations segment

The other holdings and corporate operations segment includes our holdings in subsidiaries, affiliates and other companies engaged in various fields of advanced technology, and corporate operations which provide strategic and operational support to our group companies. The following table sets forth this segment's operating results:

	Three months e	ended June 30,	Six months end	led June 30,
	2005	2004	2005	2004
	(million	s of \$)	(millions	of \$)
Net revenues	3.3	1.8	6.2	3.6
Net loss from equity investments	(4.2)	(1.7)	(7.8)	(2.1)
Gains from disposal of business and				
affiliated companies and changes in				
holdings in affiliated companies	22.4	21.8	22.4	27.9
Other income, net	<u>56.3</u>	<u>1.7</u>	<u>56.5</u>	<u>4.2</u>
Total income	<u>77.7</u>	<u>23.6</u>	<u>77.3</u>	<u>33.6</u>
Cost of revenues	1.9	1.2	3.6	2.3
Operating expenses*	4.5	3.4	8.3	9.0
Amortization of other assets	0.1	-	0.1	-
Finance income, net	(3.2)	<u>(0.1)</u>	<u>(4.1)</u>	(0.4)
Total costs and expenses	<u>3.3</u>	<u>4.5</u>	<u>8.0</u>	<u>10.9</u>
Gain from continuing operations				
before income taxes	74.4	19.1	69.4	22.7
Income taxes	(26.0)	(7.5)	(25.9)	(8.1)
Minority interest	<u>0.5</u>	(5.5)	<u>0.6</u>	(3.9)
Net income	<u>48.8</u>	<u>6.1</u>	<u>44.1</u>	<u>10.7</u>

^{*} Excluding amortization of intangible assets which are presented separately.

Income

Net revenues. Net revenues in the three and six month periods ended June 30, 2005 and 2004 of the Other Holdings and Corporate Operations segment consisted of sales of products and services by our subsidiaries, mainly Galil Medical and SELA. The following table sets forth the segment revenues:

	Three months end	led June 30,	Six months ended June 30,		
	2005	2004	2005	2004	
		(millions o	of \$)		
Galil Medical	2.2	1.7	4.1	3.4	
SELA ¹	1.1	-	2.0	-	
Other	Ξ.	<u>0.1</u>	<u>0.1</u>	<u>0.2</u>	
	<u>3.3</u>	<u>1.8</u>	<u>6.2</u>	<u>3.6</u>	

¹ SELA's results have been consolidated since July 1, 2004

In the three and six month periods ended June 30, 2005, Galil Medical recorded revenues of \$2.2 million and \$4.1 million, compared to \$1.7 million and \$3.4 million in the same periods of 2004. Galil Medical's revenues derived mainly from the supply of cryo products and R&D services to Oncura, in which it has a 25% ownership interest.

SELA recorded revenues of \$1.1 million and \$2.0 million in the three and six month periods ended June 30, 2005 compared to \$0.9 million and \$1.8 million in the same periods of 2004.

Share in net losses of affiliated companies. Our share in net losses of affiliated companies resulted from our holdings in certain investments that are accounted for under the equity method (see above under "Basis of Presentation"). Our share in net losses of affiliated companies amounted to \$4.2 million and \$7.8 million in the three and six month periods ended June 30, 2005, compared to \$1.7 million and \$2.1 million in the same periods in 2004. The increase in our share in net losses of our affiliated companies is primarily due to the sale of our holding in Elbit Systems during the third quarter of 2004, which positively contributed \$2.2 million and \$4.7 million to our net income in the three and six month periods ended June 30, 2004. In addition, amortization of intangible assets relating to our holdings in our group companies, which is included in our share in net losses of affiliated companies, has increased in the three and six month periods ended June 30, 2005 to \$3.4 million and \$1.7 million, from \$0.8 million and \$1.2 million in the comparable periods in 2004, mainly due to the purchase of additional shares of Given Imaging during the second half of 2004. Our share in net losses of affiliated companies in the three and six month periods ended June 30, 2005 also includes a loss of \$1.1 million and \$1.8 million, representing our share in Oren's net loss, which will not recur in future periods due to our sale of all of our shares in Oren, as described above under "RECENT DEVELOPMENTS".

Highlights of the Results of Operations of Our Major Affiliates:

Given Imaging (Nasdaq: GIVN) (a 20% holding directly and indirectly through RDC). Given Imaging Ltd. ("Given Imaging"), a medical device company that develops, manufactures and markets innovative diagnostic system for visualizing the gastrointestinal tract, using a a disposable miniature imagin capsules, recorded revenues of \$20.5 million and \$42.5 million in the three and six month periods ended June 30, 2005, an increase of 33% and 51% over the revenues recorded in the same periods of 2004 of \$15.5 million and \$28.2 million. Given Imaging's net loss in the second quarter of 2005 was \$0.4 million (which included a special provision, net of tax benefits, of \$1.2 million for certain taxes related to its U.S. subsidiary), compared to a net income of \$0.9 million in the second quarter of 2004. Given Imaging's net income for the first six months of 2005 (including such special provision of \$1.2 million) was \$0.9 million similar to the net income in the same period of 2004.

Oncura (a 25% holding by Galil). Oncura, which markets and sells therapeutic device systems and related consumables used primarily in the performance of minimally-invasive, urologic cancer treatment, recorded revenues in the six month period ended June 30, 2005 of approximately \$38.4 million, compared to \$33.5 million in the same period of 2004 and its net loss amounted to \$2.2 million, compared to \$0.2 million in the same period of 2004. The increase in the net loss resulted primarily due to the increase in operating expenses, mainly selling and marketing expenses.

Notal Vision (a 26% holding). Notal Vision, a medical device company operating in the field of early detection of Age Related Macular Deterioration (AMD), recorded revenues in the six month periods ended June 30, 2005 of approximately \$0.1 million compared to approximately \$0.3 million in the same period of 2004 and its net loss increased to \$1.4 million, compared to \$0.9 million in the same period in 2004, mainly as a result of an increase in research and development expenses. In May 2005, Notal appointed TLC Vision Corporation ("TLC"), as it exclusive distributor for the sale and distribution of its home device in North America. TLC also signed an investment agreement with Notal, pursuant to which TLC committed to invest \$4.25 million in Notal (of which \$1 million has already been invested) subject to achievement of milestones, primarily for the purpose of funding the development of the home device.

NetVision (a 39% holding) (TASE: NTSN). NetVision provides Internet services and solutions in Israel and, commencing in the fourth quarter of 2004, international telephony services through Voice over IP technology (VoIP). NetVision's revenues increased in the three and six month periods ended June 30, 2005 by 9% and 10% to 18.3 million and \$36.2 million (of which \$0.7 million and \$1.3 million derived from international telephony services) from \$16.8 million and \$33.0 million in the same periods in 2004 and its customer base at June 30, 2005 reached approximately 406,000 (of which approximately 247,000 were broadband) compared to 390,000 at the end of 2004 (of which approximately 225,000 were broadband). Operating income of NetVision's core business of providing Internet connectivity for the three and six month periods ended June 30, 2005 increased in both periods by 24% to \$3.1 million and \$5.7 million, compared to \$2.5 million and \$4.7 million in the same periods in 2004. Due to costs related to the launch of its international telephony services, NetVision's consolidated operating income amounted to \$2.6 million and \$3.7 million, compared to \$2.6 million and \$4.7 million in the same periods in 2004 and its consolidated net income decreased to \$1.2 million and \$1.3 million compared to \$1.8 million and \$2.3 million in the same periods in 2004. NetVision's operating currency is the New Israeli Shekel (NIS) and accordingly, all figures above are translations for convenience purposes of NetVision's NIS figures into US dollars at the representative rate of exchange prevailing at June 30, 2005 according to which \$1.00 equaled NIS 4.574.

NetVision's future period results will continue to be affected mainly by the highly competitive Internet broadband market environment in Israel, and whether Internet prices will continue to decrease or will stabilize, as well as from costs incurred in connection with penetrating the highly competitive international telephony services market in Israel.

On May 19, 2005, NetVision completed its initial public offering on the TASE of shares and convertible securities in consideration for aggregate immediate net proceeds of approximately \$31 million (see above under "RECENT DEVELOPMENT").

Wavion (a 38% holding). Wavion is a developer of broadband wireless access systems for wireless LANs. Wavion's net loss amounted to \$1.5 million and \$3.1 million in the three and six month periods ended June 30, 2005, as compared to \$1.4 million and \$3.1 million in the comparable periods in 2004, consisting mainly of research and development expenses.

ChipX (a 27% holding). ChipX is a manufacturer of late stage programmable application-specific integrated circuits, or structured ASICs. ChipX's revenues in the three and six month periods ended June 30, 2005 increased to \$4.0 million and \$9.0 million, compared to \$3.9 million and \$7.8 million in the same period in 2004, and its net loss decreased to \$1.3 million and \$1.8 million, compared to \$1.5 million and \$3.0 million in the same periods in 2004. In March 2004, ChipX raised \$12.0 million in a private placement, the proceeds of which are used to finance its sales, marketing and development investments in its structured ASIC technology.

AMT (a 41% holding). The AMT group develops technologies and products based on amorphous metals. AMT's consolidated revenues in the three and six month periods ended June 30, 2005, amounted to \$1.1 million and \$1.8 million, compared to \$0.6 million and \$1.0 million in the same period of 2004 and its consolidated net loss amounted to \$0.6 million and \$1.4 million, compared to \$0.7 million and \$1.1 million in the same periods in 2004. AMT's main subsidiary, AHT, which uses amorphous metals for heating products, recorded revenues of \$0.7 million and \$1.2 million in the three and six month periods ended June 30, 2005, compared to \$0.3 million and \$0.5 million in the same period in 2004, and a net loss of \$0.3 million and \$0.7 million, compared to \$0.4 million and \$0.7 million in the same periods in 2004. In June 2004 AMT completed a private placement of \$6.0 million, in which an international strategic partner invested \$3.0 million and we invested an additional \$3.0 million.

We expect that most of our group companies will continue to recognize losses in future periods, as they invest significant resources in research and development and sales and marketing activities and have not yet generated significant revenues. Therefore, we anticipate that our share in the results of our group companies will continue to negatively affect our results of operations to the extent they are reported under the equity or consolidation method of accounting. In addition, following the sale of our holding in Elbit Systems in 2004 which positively contributed to our net income in previous periods, and in light of expected investments in new companies, to the extent they will be accounted for under the equity method of accounting, our share in the net losses of our group companies may increase.

Results of operations of significant group companies which are accounted for other than under the equity method of accounting and whose results do not affect our results of operations.

Partner (Nasdaq: PTNR) (a 2% holding). Partner is a Global System for Mobile Communications, or GSM, mobile telephone network operator in Israel. Our investment in Partner is accounted for as available-for-sale securities. Following the sale of the majority of our shares in Partner during the second quarter of 2005 (see above under "RECENT DEVELOPMENTS"), the market value of our investment in Partner as of June 30, 2005 amounted to \$22.1 million. The majority of the remaining Partner shares held by us, amounting to approximately 3.1 million shares, are subject to certain transfer restrictions under Partner's Israeli communications license but are no longer pledged to Partner's lending banks.

In the three and six month periods ended June 30, 2005, Partner recorded revenues of \$273.5 million and \$549.0 million compared to \$274.3 million and \$540.7 million in the same periods in 2004 and its net income amounted to \$25.3 million and \$52.5 million, compared to \$29.2 million and \$49.2 million in the comparable periods in 2004. Partner's subscriber base as of June 30, 2005 was 2,409,000 compared to 2,340,000 at the end of 2004. Partner's operating currency is the NIS and accordingly, all figures above are translations for convenience purposes of Partner's NIS figures into US dollars at the representative rate of exchange prevailing at June 30, 2005 according to which \$1.00 equaled NIS 4.574.

Teledata (a 28% holding). Teledata provides innovative access products and solutions for both traditional and next generation networks to telecom operators and service providers. Teledata's revenues in the six month period ended June 30, 2005 amounted to \$26.7 million. In May 2005, Teledata completed a private placement of \$19 million, the proceeds of which will be used to finance the expansion of its product offering.

Jordan Valley (a 28% holding). Jordan Valley is engaged in developing solutions for advanced in-line thin film metrology for the semiconductor industry. Jordan Valley's revenues in the three and six month periods ended June 30, 2005 increased to \$5.5 million and \$6.4 million from \$0.5 million and \$1.1 million in the same periods in 2004, primarily due to the launch of new products, and it reported net income of \$1.4 million and \$0.6 million, compared to a net loss of \$1.0 million and \$1.8 million in the same periods in 2004. In October 2004, Jordan Valley completed a private placement of approximately \$9 million, the proceeds of which are being used to finance its sales, marketing and development activities.

Impliant (a 28% holding). Impliant is engaged in the development of an innovative posterior motion preservation system for spine surgery. Impliant's net loss in the three and six month periods ended June 30, 2005 amounted to \$1.7 million and \$3.2

million, compared to \$0.7 million and \$1.2 million in the same periods in 2004, mainly as a result of increase in research and development expenses, following the completion of its private placement of approximately \$18 million in December 2004.

Gains from Disposal of Business and Affiliated Companies and Changes in Holdings in Affiliated Companies. Our gains from disposal of businesses and affiliated companies and changes in our holdings in affiliated companies amounted in both periods of the three and six month periods ended June 30, 2005 to \$22.4 million, compared to \$21.8 million and \$27.9 million in the same periods in 2004. The gain in the three and six month periods ended June 30, 2005 resulted primarily from the following: (i) a gain of approximately \$19.7 million (which after income taxes amounted to \$17.2 million) resulting from the sale of Oren's shares in consideration for \$20.3 million; and (ii) a gain of approximately \$3.0 million from the decrease in our interest in NetVision following its initial public offering.

The gain recorded in the second quarter of 2004 resulted primarily from the following: (i) a \$15.2 million gain (which after minority interest and income taxes amounted to \$6.7 million) resulting from the sale of 300,000 shares of Given Imaging by RDC and the decrease in our direct and indirect interest in Given Imaging following Given Imaging's secondary public offering; and (ii) a gain of \$5.8 million (which after minority interest and income taxes amounted to \$1.4 million) resulting from the purchase by RDC of treasury shares amounting to approximately 3% of its outstanding shares from one of its shareholders (a former senior executive of RDC) in consideration for distribution of 200,000 shares of Given Imaging. The gain in the six month period ended June 30, 2004 also included a \$5.3 million gain from the sale of our share of KIT eLearning, for a cash payment of \$9.4 million (from which we received \$5.7 million) and a future payment of up to an additional \$10.0 million based on future earnings of KIT in 2006 and 2007 (from which our share will be up to \$5.7 million).

Other Income, net. Other income, net, of the other holdings and corporate operations segment amounted to \$56.3 million and \$56.5 million in the three and six months period ended June 30, 2005 compared to \$1.7 million and \$4.2 million in same period in 2004. The gain in both of the three and six month periods ended June 30, 2005 was primarily due to a \$56.4 million gain (which after income taxes amounted to \$36.0 million) from the sale of 12,765,190 shares of Partner for approximately \$94.0 million. The gain in the second quarter of 2004 resulted mainly from a \$1.9 million gain, before tax, from the sale of 271,812 shares of Zix which were received in consideration for ESW's assets and business sold to Zix in 2003. The gain in the six month period ended June 30, 2004 also included a \$3.1 million gain, before tax, from the sale of 362,416 shares of Zix during the first quarter of 2004 which was partially offset by \$0.5 million, representing the funding of 3DV's previous years' losses.

Expenses

Cost of revenues. Cost of revenues consisted primarily of expenses related to salaries and hardware associated with delivering products and services of our subsidiaries, mainly Galil Medical and SELA (whose results have been consolidated since July 1, 2004). Cost of revenues of the Other Holdings and Corporate Operation segment in the three and six month periods ended June 30, 2005 amounted to \$1.9 million and \$3.6 million, compared to \$1.2 million and \$2.3 million in the same periods in 2004.

Operating expenses. Operating expenses are comprised of research and development expenses, sales and marketing and general and administrative expenses of our and RDC's corporate operations and of our subsidiaries, mainly Galil Medical, SELA, 3DV and Starling. The following table sets forth the segment operating expenses (excluding amortization of intangible assets which is presented separately and amounted to \$0.1 million in the three and six months ended June 30, 2005 and \$0 in the same periods of 2004, which also constitute part of operating expenses under US GAAP but for presentation purposes are included as a separate item):

	Three months end	led June 30,	Six months ended June 30,		
	2005	2004	2005	2004	
		(millions	of \$)		
Corporate	2.1	1.7	3.9	3.7	
Galil Medical	0.7	0.6	1.5	1.4	
$SELA^1$	0.8	-	1.6	-	
Starling	0.6	0.1	1.0	0.5	
3DV	0.6	0.4	0.9	0.8	
Other	(0.3)	<u>0.6</u>	(0.6)	<u>2.6</u>	
	<u>4.5</u>	<u>3.4</u>	<u>8.3</u>	<u>9.0</u>	

¹SELA's results have been consolidated since July 1, 2004

Operating expenses of Galil Medical in the three and six month periods ended June 30, 2005 amounted to \$0.7 million and \$1.5 million, as compared to \$0.6 million and \$1.4 million in the same periods in 2004 and its operating results amounted to operating income of \$0.1 million and operating loss of \$0.1 million compared to \$0 million and operating loss of \$0.2 million in the same periods in 2004, mainly as a result of the increase in revenues. At the end of 2004 Galil commenced the development of its cryotherapy technology for application in the women's health field.

SELA's operating expenses amounted to \$0.8 million and \$1.6 million in the three and six month periods ended June 30, 2005, compared to \$0.6 million and \$1.2 million in the same periods in 2004 and its operating loss amounted to \$0.2 million and \$0.4

million compared to \$0.1 million and \$0.2 million. The increase in the operating loss resulted from the increase in operating expenses, mainly research and development and selling and marketing expenses.

Other operating expenses include mainly the operating expenses of RDC which included, in three and six month periods ended June 30, 2005 an income of \$0.7 million and \$1.3 million relateing to RDC's employee stock option plans and resuling from the decrease in the fair value of call options to purchase shares of affiliated companies, compared to \$0.4 million and \$2.2 million costs in the same periods of 2004.

Finance income, net. Finance income, net, in the corporate operations and other holdings segment amounted in the three and six month periods ended June 30, 2005 to \$3.2 million and \$4.1 million, compared to \$0.1 million and \$0.4 million in the same periods in 2004. The increase is mainly due to higher cash resources as a result of the sale of our holding in Elbit Systems in 2004 for approximately \$197 million and from the sale of Partner shares in the second quarter of 2005 for approximately \$94.0 million.

Income Taxes. Income taxes, net, in the three and six month periods ended June 30, 2005 were \$26.0 million and \$25.9 million, which resulted mainly from the sale of Partner shares and the sale of Oren Shares.

Income taxes, net, in the three and six month periods ended June 30, 2004 were \$7.5 million and \$8.2 million, which resulted mainly from the secondary public offering of Given Imaging, the purchase of treasury stock in RDC in consideration for distribution of Given Imaging's shares and the sale of Zix shares.

LIQUIDITY AND CAPITAL RESOURCES

Consolidated cash, debentures and deposits at June 30, 2005, were approximately \$253.0 million compared with \$188.6 million at December 31, 2004. At June 30, 2005, corporate cash, debentures and deposits were \$242.4 million compared with \$175.7 million at December 31, 2004. The increase is mainly due to proceeds received from the sale of Partner shares in the second quarter of 2005 of approximately \$94.0 million.

The main sources of corporate cash and other liquid instruments in the six month period ended June 30, 2005, were \$94.0 million of proceeds from the sale of Partner shares, \$10.1 million cash proceeds from the sale of our shares in Oren and \$2.2 million repayment of loan by NetVision.

The main uses of corporate cash and other liquid instruments in the six month period ended June 30, 2005, were an income tax payment of approximately \$15 million (mainly with respect to the sale of Elbit Systems in 2004) and \$22.8 million of investments in new and existing group companies (which mainly include investments of \$16.0 million in Teledata, \$1.7 million in NuLens and \$1.5 million in Starling).

In order to hedge the dollar value received from the sale of our shares in Partner, we purchased call options and sold put options, at a dollar/NIS exchange rate ranging from \$4.36 to \$4.44. The hedge transaction had no material effect on our cash resources and our results of operations.

Consolidated working capital at June 30, 2005 amounted to \$222.7 million compared to \$158.8 million at December 31, 2004. The increase is mainly due to proceeds received from the sale of Partner shares in the second quarter of 2005 of approximately \$94 million.

Consolidated loans at June 30, 2005, were approximately \$9.0 million (of which \$2.0 million were attributed to Elron TeleSoft, and which are guaranteed by us), compared to \$9.1 million at December 31, 2004. In connection with some of Elron TeleSoft's bank loans, we have also provided to the lending bank a comfort letter pursuant to which we undertook not to reduce our holding beyond a certain percentage. MediaGate's bank loan in the amount of approximately \$2.7 million has been secured by a first ranking pledge over the future proceeds to be received as royalties as a consideration for the sale of its technology to Telrad. The loan is not guaranteed by us.

The remaining Partner shares held by us as of June 30, 2005, amounting to approximately 3.1 million shares, are subject to certain transfer restrictions under Partner's Israeli communications license but are no longer pledged to Partner's lending banks.

Our investment policy for managing our funds is in general to invest in bank deposits and U.S. government securities with high liquidity.

We believe that our existing capital will be sufficient to fund our and our subsidiaries' operations and our investment plan in existing and new companies for at least the next twelve months.

Shareholders' equity at June 30, 2005, was approximately \$381.6 million, representing approximately 81% of the total assets compared with \$389.1 million representing approximately 78% of total assets at December 31, 2004. The decrease in the shareholders' equity despite the significant gain we recorded in the first half of 2005 resulted mainly from the decrease in other comprehensive income as a result of the sale of Partner.

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

As of June 30, 2005 (Unaudited)

CONDENSED INTERIM CONSOLIDATED

FINANCIAL STATEMENTS

AS OF JUNE 30, 2005

UNAUDITED

INDEX

	Page
Consolidated Balance Sheets	1-2
Consolidated Statements of Operations	3
Statements of Shareholders' Equity	4-5
Consolidated Statements of Cash Flows	6-7
Notes to the Consolidated Financial Statements	8-15
Annex to the Consolidated Financial Statements	16

.

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands, except share and per share data

	 une 30, 2005 naudited	 ecember 31, 2004 Audited
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 119,091	\$ 42,611
Short-term investments	142,056	146,009
Trade receivables, net*	6,390	6,112
Other receivables and prepaid expenses*	3,478	1,946
Inventories and contracts-in-progress	 2,384	 1,984
Total current assets	 273,399	 198,662
INVESTMENTS AND LONG-TERM RECEIVABLES		
Investments in affiliated companies	112,541	117,124
Investments in other companies and long-term receivables*	58,327	155,929
Deferred taxes	3,957	5,493
Severance pay deposits	 2,401	 2,637
Total investments and long-term receivables	 177,226	 281,183
PROPERTY AND EQUIPMENT, NET	 7,925	8,064
INTANGIBLE ASSETS		
Goodwill	8,939	10,268
Other intangible assets	2,953	2,979
0 mer man91910 a 00000	 2,755	 -, ,,,
Total intangible assets	 11,892	 13,247
Total assets	\$ 470,442	\$ 501,156

^{*} Includes receivables from related parties in the aggregate amount of \$4,307 and \$3,360 as of June 30, 2005 and December 31, 2004, respectively.

CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands, except share any

U.S. dollars in thousands, except share and per share data			
	 une 30, 2005 naudited		ecember 31, 2004 Audited
LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES Short-term loans from banks and others Current maturities of long-term loans from banks and others Trade payables Other payables and accrued expenses	\$ 2,003 2,809 2,431 43,445	\$	2,079 2,974 3,459 31,333
Total current liabilities	 50,688		39,845
LONG-TERM LIABILITIES Long-term loans from banks and others Accrued severance pay and retirement obligations Deferred taxes Other	 4,200 3,567 7,585		4,072 3,809 41,233 22
Total long-term liabilities	 15,352		49,136
MINORITY INTEREST	22,833		23,095
SHAREHOLDERS' EQUITY: Ordinary shares of NIS 0.003 par value; Authorized - 35,000,000 shares as of June 30, 2005 and December 31, 2004; Issued and outstanding - 29,416,924 shares as of June 30, 2005 and 29,414,424 shares as of December 31, 2004 Additional paid-in capital Accumulated other comprehensive income Retained earnings	9,572 270,187 7,937 93,873		9,572 270,005 57,717 51,786
Total shareholders' equity	 381,569	ī	389,080
Total liabilities and shareholders' equity	\$ 470,442	\$	501,156

CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands, except share and per share data

	Six months ended June 30,					Three mo	onths ne 30.		Year ended December 31		
		2005		2004		2005		2004		2004	
				Una	udite	d				Audited	
INCOME											
Net revenues*	\$	8,518	\$	7,001	\$	4,260	\$	3,576	\$	16,330	
Equity in losses of affiliated companies Gain from disposal of businesses and affiliated companies and changes in		(7,827)		(2,098)		(4,244)		(1,709)		(10,492)	
holdings in affiliated companies, net		22,389		27,901		22,399		21,821		132,396	
Other income, net		56,548		4,187		56,262		1,750		4,784	
Other meome, net								•			
COCKE AND EXPENSES		79,628		36,991		78,677		25,438		143,018	
COSTS AND EXPENSES		4.017		4.400		2 427		2.424		0.650	
Cost of revenues		4,917		4,489		2,427		2,434		9,650	
Research and development costs, net		3,229		1,570		1,675		556		3,637	
Marketing and selling expenses, net		2,333		1,190		1,233		624		3,202	
General and administrative expenses		4,639		7,644		2,492		2,989		13,285	
Restructuring costs		1.62		200		110		106		225	
Amortization of intangible assets		163		390		119		196		731	
Impairment of goodwill Impairment of intangible assets and property and equipment		1,329		-		1,329		-		1,980 7,097	
Financial expenses (income), net		(4,311)		102		(3,389)		- 57		(643)	
r-mancial expenses (meome), net	_		-		_				-		
		12,299		15,385		5,886		6,856		39,164	
Income before taxes on income		67,329		21,606		72,791		18,582		103,854	
Taxes on income		25,887		8,154		26,042		7,512		15,132	
Income from continuing operations after taxes											
on income		41,442		13,452		46,749		11,070		88,722	
Minority interest in losses (income) of											
subsidiaries		645		(3,895)		451		(5,535)		(4,135)	
Income from continuing operations		42,087		9,557		47,200		5,535		84,587	
Loss from discontinued operations		-		(356)		-		(56)		(454)	
Net income	\$	42,087	\$	9,201	\$	47,200	\$	5,479	\$	84,133	
Income (loss) per share: Basic:											
Income from continuing operations Loss from discontinued operations	\$	1.43	\$	0.33 (0.01)	\$	1.60	\$	0.19	\$	2.89 (0.02)	
Net income	\$	1.43	\$	0.32	\$	1.60	\$	0.19	\$	2.87	
	φ	1.43	Ψ	0.52	φ	1.00	Ψ	0.17	φ	2.07	
Diluted:	Ф	1.40	Ф	0.22	Ф	1.60	Ф	0.10	Ф	2.00	
Income from continuing operations Loss from discontinued operations	\$	1.42	\$	0.32	\$	1.60	\$	0.19	\$	2.88	
-	_			(0.01)		-	_			(0.02)	
Net income	\$	1.42	\$	0.31	\$	1.60	\$	0.19	\$	2.86	
Weighted average number of ordinary shares used in computing basic net income per share (thousands)	_	29,415		29,211		29,416	· <u></u>	29,212		29,266	
Weighted average number of ordinary shares used in computing diluted net income per share (thousands)		29,543		29,323	. <u></u>	29,538		29,340		29,385	

^{*} Includes revenues from related parties, in the amount of \$4,110 and \$4,303 for the six months ended June 30, 2005 and 2004, respectively, an amount of \$2,144 and \$2,065 for the three months ended June 30, 2005 and 2004, respectively, and an amount of \$8,480 for the year ended December 31, 2004.

STATEMENTS OF SHAREHOLDERS' EQUITY

U.S. dollars in thousands, except share and per share data

Balance as of January 1, 2004 29,206,845 29,572 267,113 51,792 296,130 296,130 296,130 207,575 2		Number of shares	Sha	are capital		Additional d-in capital		ccumulated other mprehensive income		Retained earnings ccumulated deficit)	Si	Total hareholders' equity		Total mprehensive acome (loss)
Exercise of options		20 206 845	•	0.572	•	267 113	•	51 702	•	(32 347)	Φ.	206 130		
Stack based compensation Stack based compens	• ,	, ,	φ	9,312	φ		φ	31,792	φ	(32,347)	φ			
Tax benefit in respect of options exercised 19		,		-				-		-		,		
Reclassification adjustment for gain realized included in net income	Tax benefit in respect of options exercised	-		-		250		-		-		250		
Reclassification adjustments for gain realized included in net income income recover translation adjustments														
1000mg 1		-		-		-		8,489		-		8,489	\$	8,489
Protein currency translation adjustments								(2.592)				(2.592)		(2.592)
Propertical gain on derivative instruments in affiliated company Reclassification adjustments for loss on derivative instruments and foreign currency translation adjustments for loss on derivative instruments and foreign currency translation adjustments for loss on derivative instruments and foreign currency translation adjustments for loss on derivative instruments and foreign currency translation adjustments for loss on derivative instruments in affiliated companies Realeasification adjustments for loss on derivative instruments in affiliated company (adjustment) for a single for sale securities (adjustment) for gain realized included in net income (adjustment) for gain realized		-		-		-				-				
Reclassification adjustments for loss on derivative instruments, minimum penson liability and foreign currency translation adjustments, included in net income due to sale of affiliated companies (companies) (-		-		_				_				
Part								04				04		04
Adjustments, included in net income due to sale of affiliated companies														
Net income														
Salance as of December 31, 2004	companies	-		-		-		732		-				732
Total comprehensive income	Net income	-								84,133		84,133		84,133
Namidited Series of options Series Serie		29,414,424	\$	9,572	\$	270,005	\$	57,717	\$	51,786		389,080	¢.	00.059
Exercise of options	1												2	90,058
Stock based compensation		2 500				10						10		
Other comprehensive income (loss), net of tax: Unrealized losses on available for sale securities Reclassification adjustment for gain realized included in net income Income income (loss), net of tax: Reclassification adjustments		2,300		-				-		-				
Unrealized losses on available for sale securities Reclassification adjustment for gain realized included in net income I						103						103		
Reclassification adjustment for gain realized included in net income		_		_		_		(13.252)		_		(13,252)	\$	(13,252)
Foreign currency translation adjustments Net income								. , ,				. , ,		. , ,
Net income		-		-		-				-				
Ralance as of June 30, 2005 29,416,924 9,572 \$270,187 \$7,937 \$93,873 \$381,569 (7,693)		-		-		-		(163)		-				` '
Total comprehensive loss Sunautive Comprehensive Compr	Net income					-				42,087		42,087		42,087
Unaudited Balance as of January 1, 2004 29,206,845 9,572 267,113 51,792 (32,347) 296,130 Exercise of options 13,500 - 93 - - 93 Stock based compensation - - 312 - - 93 Other comprehensive income (loss), net of tax: - - - 552 - 552 \$ 552 Reclassification adjustment for gain realized included in net income - - - - 552 - 552 \$ 552 Foreign currency translation adjustments - - - - - 292 - 292 292 Unrealized gain on derivative instrument in affiliated company - - - - 84 - 84 84 Net income - - - - - 9,201 9,201 9,201		29,416,924	\$	9,572	\$	270,187	\$	7,937	\$	93,873	\$	381,569		
Balance as of January 1, 2004 29,206,845 \$ 9,572 \$ 267,113 \$ 51,792 \$ (32,347) \$ 296,130 Exercise of options 13,500 - 93 - - 93 Stock based compensation - - 312 - - 312 Other comprehensive income (loss), net of tax: - - - - 552 - 552 \$ 552 Reclassification adjustment for gain realized included in net income - - - - 552 - 552 \$ 552 Foreign currency translation adjustments - - - - - 292 - 292<													\$	(7,693)
Exercise of options 13,500 - 93 93 Stock based compensation - 312 -														
Stock based compensation - - 312 - - 312 - - 312 - - 312 - - 312 - - 312 - - 312 - - 312 - - 312 - - 312 - - 312 - - 312 - - - 312 - - - - - - - -			\$	9,572	\$,	\$	51,792	\$	(32,347)	\$			
Other comprehensive income (loss), net of tax: Unrealized gains on available-for-sale securities Reclassification adjustment for gain realized included in net income Foreign currency translation adjustments Unrealized gain on derivative instrument in affiliated company Net income Other comprehensive income (loss), net of tax: 552 - 552 - 552 - 552 - (3,309) - (3,309) - (3,309) - 292 - 292 - 292 - 292 Unrealized gain on derivative instrument in affiliated company Net income Net income		13,500		-				-		-				
Unrealized gains on available-for-sale securities - - - 552 - 552 \$552 Reclassification adjustment for gain realized included in net income - - - (3,309) - (3,309) - (3,309) - 292 - 292 292 - 292 292 292 - 292 292 - 84 84 - 84 84 84 84 Net income - - - - - - 9,201 9,201 9,201 9,201		-		-		312		-		-		312		
Reclassification adjustment for gain realized included in net income - - - (3,309) - (3,309) (3,309) Foreign currency translation adjustments - - - 292 - 292 292 Unrealized gain on derivative instrument in affiliated company - - - 84 - 84 84 Net income - - - - 9,201 9,201 9,201		_		_		_		552		_		552	\$	552
income (3,309) - (3,309) - (3,309) Foreign currency translation adjustments 292 - 292 Unrealized gain on derivative instrument in affiliated company 84 - 84 Net income 9,201 9,201 9,201								332				332	Ψ	332
Foreign currency translation adjustments - - - 292 - 292 292 Unrealized gain on derivative instrument in affiliated company - - - 84 - 84 84 Net income - - - - - 9,201 9,201 9,201		_		_		_		(3.309)		_		(3,309)		(3.309)
Unrealized gain on derivative instrument in affiliated company - - - 84 - 84 84 Net income - - - - - - 9,201 9,201 9,201	Foreign currency translation adjustments	_		-		-				_				
	Unrealized gain on derivative instrument in affiliated company	-		-		-		84		-				
Ralance as of June 30 2004 29 220 345 \$ 9.572 \$ 267.518 \$ 49.411 \$ (23.146) \$ 303.355	Net income	-								9,201		9,201		9,201
27,220,343 \$\psi\$ 207,310 \$\psi\$ 47,411 \$\psi\$ (23,140) \$\psi\$ 303,333	Balance as of June 30, 2004	29,220,345	\$	9,572	\$	267,518	\$	49,411	\$	(23,146)	\$	303,355		
Total comprehensive income \$ 6,820	Total comprehensive income												\$	6.820

STATEMENTS OF SHAREHOLDERS' EQUITY

U.S. dollars in thousands, except share and per share data

	Number of shares	Share cap	ital	Additional paid-in capita	c	Accumulated other omprehensive income	ea (Acc	etained arnings umulated leficit)	SI	Total hareholders' equity		Total mprehensive come (loss)
Unaudited												
Balance as of April 1, 2005	29,414,424	9,5	72	270,114		63,080		46,673		389,439		
Exercise of options	2,500		-	19		-		-		19		
Stock based compensation	-		-	54		-		-		54		
Other comprehensive income (loss), net of tax:												
Unrealized losses on available for sale securities	-		-	-		(18,586)				(18,586)	\$	(18,586)
Reclassification adjustment for gain realized included in net												
income	-		-	-		(36,365)				(36,365)		(36,365)
Foreign currency translation adjustments	-		-	-		(192)		-		(192)		(192)
Net income			-		_			47,200		47,200		47,200
Balance as of June 30, 2005	29,416,924	\$ 9,5	12	\$ 270,187	\$	7,937	\$	93,873	\$	381,569		
Total comprehensive loss											\$	(7,943)
Unaudited												
Balance as of April 1, 2004	29,211,345	\$ 9,5	12	\$ 267,327	\$	54,096	\$	(28,625)	\$	302,370		
Exercise of options	9,000	Ψ 2,3	_	62	Ψ	34,070	Ψ	(20,023)	Ψ	62		
Stock based compensation	2,000		-	129				_		129		
Other comprehensive income (loss), net of tax:	-		-	129				_		129		
Unrealized losses on available-for-sale securities						(3,406)		_		(3,406)	\$	(3,406)
Reclassification adjustment for gain realized included in net	-		-	-		(3,400)		_		(3,400)	Ψ	(3,400)
income	_		_	_		(1,264)		_		(1,264)		(1,264)
Foreign currency translation adjustment						(117)				(117)		(117)
Unrealized gain on derivative instrument in affiliated company	_		-			102				102		102
Net income	-		_	-		102		5,479		5,479		5,479
- Tet income		-		-				3,477		3,477	-	3,477
Balance as of June 30, 2004	29,220,345	\$ 9,5	12	\$ 267,518	\$	49,411	\$	(23,146)	\$	303,355		
Total comprehensive income	<u> </u>					<u> </u>		/		<u> </u>	\$	794
											<u> </u>	

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands						
		Six 1 ended	nonth June			ar ended ember 31,
-		2005	0 44110	2004	200	2004
		Una	udited		A	udited
Cash flows from operating activities						
	\$	42,087	\$	9,201	\$	84,133
Adjustments to reconcile net income to net cash used in operating activities:		7 927		2.000		10.402
Equity in losses of affiliated companies Dividend from affiliated companies		7,827		2,098 1,719		10,492 1.719
Minority interest in income (losses) of subsidiaries		(645)		3,895		4,135
Ggain from disposal of businesses and affiliated companies and changes in		(0-3)		3,673		4,133
holdings in affiliated companies, net		(22,389)		(27,901)		(132,396)
Gain from sale of investments in available for sale securities		(56,423)		(4,995)		(5,360)
Depreciation and amortization		690		957		1,868
Impairment of intangible assets and property and equipment		-		-		7,097
Impairment of goodwill		1,329		-		1,980
Decline in value of other investments		636		150		803
Equity in losses of partnerships		60		31		7
Amortization of deferred stock compensation and changes in liability in respect		(4.4.00)		• • • •		
of call options		(1,128)		2,846		3,033
Deferred taxes, net		(4,645)		4,940		(2,409)
Changes in operating assets and liabilities Decrease (increase) in trade receivables		(279)		240		(120)
Decrease (increase) in trade receivables Decrease (increase) in other receivables and prepaid expenses		(278) (112)		349 270		(139) 88
Decrease in trading securities, net		(112)		3		5
Decrease (increase) in inventories and contracts—in-progress		(400)		79		333
Decrease in trade payables		(1,028)		(1,201)		(1,184)
Increase in other payables and accrued expenses (mainly provision for income		(1,020)		(1,201)		(1,101)
taxes)		12,854		2,807		16,935
Other		(368)		654		(798)
Net cash used in operating activities		(21,932)		(4,098)		(9,658)
Cash flows from investing activities						· · · · · · · · · · · · · · · · · · ·
Investment in affiliated companies		(3,221)		(9,899)		(57,916)
Proceeds from sale of KIT shares		-		5,706		5,706
Proceeds from sale of Oren shares		10,076		-		-
Proceeds from repayment of loan from an affiliate		2,253		-		-
Proceeds from sale of ESL shares		-		-		196,580
Proceeds from sale of Given Imaging shares		-		9,074		9,074
Proceeds from sale of Partner shares		93,978		-		-
Cash and cash equivalents resulting from newly consolidated subsidiaries (Sch. A)		- (1 < 250)		247		247
Investment in other companies		(16,350)		(667)		(15,264)
Proceeds from sale of available for sale securities Investments in deposits		957 (20,535)		6,999		8,062 (105,378)
Investment in available for sale securities		(20,333) $(18,405)$		(5,332)		(43,000)
Proceeds from maturities of held to maturity debentures and deposits		50,221		28,682		33,345
Purchase of property and equipment		(429)		(436)		(728)
Proceeds from sale of other companies		93		-		(,20)
Proceeds from sale of property and equipment		120		75		246
Purchase of treasury stock from the minority by a subsidiary		(823)		_		-
Net cash provided by investing activities		97,935		34,449		30,974
Cash flows from financing activities		· · · · · · · · · · · · · · · · · · ·				
Proceeds from options exercised		19		93		2,097
Receipt of long-term loans from banks		-		355		519
Repayment of long-term loans		(44)		(40,621)		(50,677)
Increase (decrease) in short-term bank loan, net		(76)		411		(15,842)
Receipt of short-term loans from minority shareholders of subsidiaries		-		119		137
Proceeds from convertible loans and long-term loans from minority shareholders of						
a subsidiary		500		1,402		1,402
Issuance of shares to the minority of a subsidiary		145		(100)		(100)
Issuance expenses in a subsidiary		(67)		(180)		(180)
Dividend to minority shareholders of a subsidiary		477		(67)		(67)
Net cash used in financing activities		477		(38,488)		(62,611)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		76,480		(8,137)		(41,295)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	¢	42,611	•	83,906	ф	83,906
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	\$	119,091	\$	75,769	\$	42,611

(31)

(618)

66

678

431

247

\$

\$

(1,350)

(31)

(618)

66

678

431

247

(1,350)

CONSOLIDATED STATEMENTS OF CASH FLOWS

Deposits

Property and equipment

Investment at equity prior to acquisition

Cash and cash equivalents acquired

Intangible assets

Minority interests

Long-term liabilities

			_	ear ended cember 31,	
2005		2004	2004		
 Una	<u>udited</u>			Audited	
\$ 15,025	\$	92	\$	172	
\$ 109	\$	760	\$	1,044	
\$ 2,392	\$		\$	-	
		ended		ear ended cember 31,	
		2004		2004	
	(Ur	audited)	(Audited)	
\$	ended 2005 Una \$ 15,025 \$ 109	## 15,025 \$ \$ 109 \$ \$ 2,392 \$ \$ Six	Six months ended June 30,	Six months ended June 30,	

U.S. dollars in thousands, except share and per share data

NOTE 1:- GENERAL

The accompanying unaudited condensed interim consolidated financial statements have been prepared as of June 30, 2005, and for the six and three months then ended in accordance with accounting principles generally accepted in the United States (U.S. GAAP) relating to the preparation of financial statements for interim periods. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States but which are not required for interim reporting purposes, have been condensed or omitted. See Note 7 for the reconciliation from U.S. GAAP to accounting principles generally accepted in Israel ("Israeli GAAP").

These financial statements should be read in conjunction with the Company's annual financial statements and accompanying notes as of December 31, 2004, included in Form 20-F for the year ended December 31,2004, filed with the Securities and Exchange Commission ("the Company's annual financial statements").

The condensed interim consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the periods presented.

Results for the six and three months ended June 30, 2005 are not necessarily indicative of the results that may be expected for the year ending December 31, 2005.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

- a. The significant accounting policies followed in the preparation of these financial statements are identical to those applied in preparation of the latest annual financial statements.
- b. The financial statements have been prepared in U.S. dollars, since the functional currency of the Company and its principal subsidiaries is the U.S. dollar.
- c. The Company did not provide the pro forma information as required by SFAS No. 123 when electing to follow APB Opinion 25 and its interpretations in accounting for its employee stock option plans, due to immateriality.
- d. FASB Statement No. 123 (revised 2004), "Share-Based Payment" (FAS 123(R)) (See Note 2y to the Company's annual financial statements), was to have been effective as of the beginning of the first interim or annual reporting period that commences after June 15, 2005 (July 1, 2005 for the Company); however, on April 14, 2005, the United States Securities and Exchange Commission ("SEC") delayed effectiveness of FAS 123(R) for companies with fiscal years ending December 31 (such as the Company) to January 1, 2006. The Company is currently evaluating the effect of the adoption of FAS 123(R) on its results of operations due to the application of FAS 123(R) by its affiliated companies.
- e. In March 2005, the SEC released SEC Staff Accounting Bulletin No. 107, "Share-Based Payment" ("SAB 107"). SAB 107 provides the SEC staff's position regarding the application of FAS 123(R) and contains interpretive guidance related to the interaction between FAS 123(R) and certain SEC rules and regulations, and also provides the SEC staff's views regarding the valuation of share-based payment arrangements for public companies. SAB 107 highlights the importance of disclosures made relating to the accounting for share-based payment transactions. The Company is currently reviewing the effect of SAB 107, however it does not believe that SAB 107 will have a material effect on its financial position, results of operations or cash flows.

U.S. dollars in thousands, except share and per share data

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

f. In May 2005, the FASB issued SFAS No. 154 "Accounting Changes and Errors Corrections" ("FAS 154"). FAS 154 replaces APB No. 20 "accounting changes" and SFAS No. 3 "Reporting Accounting changes in Interim Financial Statements". FAS 154 applies to all voluntary changes in accounting principle, and changes the accounting for and reporting of a change in accounting principle. FAS 154 requires, unless impracticable, retrospective application as the required method for reporting a change in accounting principle in the absence of explicit transition requirements specific to the newly adopted accounting principle. This statement also provides guidance for determining whether retrospective application of a change in accounting principle is impracticable and for reporting a change when retrospective application is impracticable. Opinion 20 previously required that most voluntary changes in accounting principle be recognized by including in net income of the period of the change the cumulative effect of changing to the new accounting principle. FAS 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. The company does not believe that FAS 154 will have a material effect on its financial statements.

NOTE 3:- MAJOR TRANSACTIONS

a. Partner

On April 20, 2005 Elbit, Elron's wholly-owned subsidiary, completed the sale of 12,765,190 Partner Communications Company Ltd. ("Partner") shares to Partner for approximately \$94,000, as part of the sale together with the other Israeli founding shareholders of Partner, of an aggregate of approximately 33.3 million Partner shares to Partner for an aggregate consideration of approximately \$245,000. As a result of the sale, Elron recorded in the statement of operations, in the second quarter of 2005, a gain of approximately \$56,400 (approximately \$36,000 net of tax).

Subsequent to the aforementioned sale, Elron's beneficial holding in Partner is approximately 2%. This interest in Partner is no longer pledged to the banks providing financing to Partner but almost all of it is still subject to certain transfer restrictions under Partner's Israeli communications license.

b. **NuLens**

On April 21, 2005, Elron completed an investment of approximately \$2,900 in NuLens Ltd. ("NuLens"), in consideration for 763,584 Series A preferred shares, as part of an aggregate investment of approximately \$3,400. NuLens is an Israeli medical devices company operating in the field of intra-ocular lenses mainly for cataract and presbyopia procedures. Elron's investment will be invested in two installments, the first of approximately \$1,700 was invested immediately for approximately 17% of NuLens on a fully diluted and on an as converted basis and an additional amount of approximately \$1,200 will be invested upon the fulfillment of a certain milestone by NuLens. Following Elron's aggregate investment, Elron will hold approximately 25% of NuLens, on a fully diluted and on an as converted basis. The investment in NuLens is accounted for under the equity method.

U.S. dollars in thousands, except share and per share data

NOTE 3:- MAJOR TRANSACTIONS (Cont.)

c. Teledata

On May 8, 2005, Elron completed an investment of \$16,000 in Teledata Networks Ltd. ("Teledata"), in consideration for 4,923,194 series A preferred shares. The investment is part of an aggregate round of financing of \$19,000, in which FBR Infinity II Ventures, an indirectly related venture capital fund, invested the remaining \$3,000. Teledata provides innovative access products and solutions for both traditional and next generation networks to telecom operators and service providers. Following the investment, Elron holds approximately 21% of Teledata, on a fully diluted and on an as converted basis. Since the investment is in preferred shares, which are not considered to be an investment that is in-substance-common stock according to the provisions of EITF 02-14, the investment in Teledata is accounted for under the cost method.

d. Netvision

On May 19, 2005, Netvision completed its initial public offering on the Tel Aviv Stock Exchange in Israel of shares and convertible securities in consideration for the immediate net proceeds of approximately NIS135 million (approximately \$31,000). Out of the proceeds received, an amount of approximately NIS38 million (approximately \$8,600) was allocated to the shares and an amount of approximately NIS97 million (approximately \$22,400) was allocated to the convertible securities. In addition, future proceeds from the exercise of options sold in the offering may amount to a maximum of approximately NIS28.8 million (approximately \$6,600). Discount Investment Corporation ("DIC"), which holds approximately 48% of Elron, is the other major shareholder of Netvision. Elron and DIC each converted approximately \$3,100 of loans into equity of Netvision immediately prior to the offering and \$2,200 in loans was repaid to each of Elron and DIC from the proceeds of the offering. As a result of the initial public offering, Elron's interest in Netvision decreased from 45.7% to approximately 39% (27.4% on a fully diluted basis taking into account the possible exercise of the convertible securities) resulting in a gain of approximately \$3,000.

e. Oren

On June 10, 2005, Zoran Corporation (NASDAQ: ZRAN) ("Zoran") completed the acquisition of Oren, in which Elron had a 41% interest. Prior to the transaction, Zoran held approximately 17% of Oren. The consideration paid by Zoran to the other shareholders in Oren was determined based on a value of Oren of \$53,500. Zoran paid approximately \$44,600 in the form of cash and Zoran common stock for the remaining 83% of Oren. Upon completion of the transaction, Elron received cash of approximately \$12,500 and Zoran common stock with a value of approximately \$7,700 (based on the market price of Zoran shares on the date of completion). As a result of the sale, Elron recorded a gain in the second quarter of 2005 of approximately \$19,700 (approximately \$17,200 net of taxes). An amount of approximately \$1,900 out of the cash received is deposited in an escrow account, half until June 2006 and half until June 2007, for the assurance of Oren's representations in accordance with the agreement.

The Zoran shares received by Elron are accounted for as available-for-sale securities. Subsequent to balance sheet date, Elron sold all shares of Zoran received by it in the transaction for approximately \$8,800 and will record a gain, in the third quarter of 2005 of approximately \$1,100 (approximately \$700 net of tax).

U.S. dollars in thousands, except share and per share data

NOTE 3:- MAJOR TRANSACTIONS (Cont.)

f. Elron Telesoft

The goodwill associated with the Systems and Projects segment (reporting unit) which consists of the operations of Elron Telesoft Ltd. and Elron Telesoft Export Ltd. ("ET group") is usually tested for impairment in the fourth quarter of each year. In light of ET group's results and level of operations, the goodwill associated with the Systems and Projects reporting unit was tested for impairment during the second quarter of 2005. As a result of the impairment test, the Company recorded impairment losses of approximately \$1,300. This impairment loss is included in a separate line item in the statement of operations. The fair value of the aforementioned reporting unit was estimated using the discounted cash flows approach.

NOTE 4:- CONTINGENT LIABILITIES

There were no material changes in the status of the Company's contingent liabilities as described in the Company's annual financial statements, the details of which are as follows:

- a. During September 1999, the Company received copies of two claims and a request to approve such claims as a class action on behalf of public shareholders of Elscint (formerly an affiliated company) against the Company and others. The allegation raised by the claimants related to the decision regarding the sale of Elscint's substantial assets. The claim has been stayed pursuant to an arrangement reached by the parties pending the outcome of the appeal in the claim described in paragraph b below. The arrangement provides that if the appeal as described in paragraph b below is accepted, then the proceedings to recognize the lawsuit as a class action will proceed. Otherwise, the application to recognize the claim as a class action suit will be dismissed.
- b. On November 2, 1999, the Company received a copy of a claim, and a request to approve such a claim, as a class action on behalf of some institutional investors and others and those who held shares in Elscint on September 6, 1999. The allegations raised against the Company and certain of its officers including former officers, among others, relate to the period prior to the sale of the Company's holdings in Elbit Medical Imaging ("EMI") (the parent company of Elscint and formerly an affiliated company). The claimants seek a court order pursuant to which EMI would be compelled to execute the alleged buy-out of Elscint's share at \$14 per share or other remedies. On August 16, 2000, the Haifa court dismissed the application to recognize the claim as a class action. Some of the claimants applied for and have been granted permission to appeal to the Supreme Court in Israel, which appeal is currently pending.

In addition, in February 2001, the claimants submitted a revised claim similar to the previous one but not as a class action. In August 2004, the Haifa District Court issued a decision ordering the cancellation of the requirement of the claimants to pay a twenty million shekels filing fee in connection with this claim. Certain of the defendants have requested permission to appeal the said decision of the Haifa District Court. It has not yet been determined when the defendants are required to file their statements of defense to the claim.

The Company denies all the allegations set forth in the above claims, and based on legal advice received, management is of the opinion that the Company has good defense arguments which, if accepted, will cause dismissal of the above allegations.

U.S. dollars in thousands, except share and per share data

NOTE 4:- CONTINGENT LIABILITIES (Cont.)

c. In July 2003, ESW terminated the lease of its premises in the U.S. due to defects in the premises and the lessor's failure to repair the defects. The lessor rejected the termination of the lease and claimed all amounts due under the lease from ESW and Elron, as guarantor of the lease. The balance of the rental under the lease amounts to approximately \$2,000. ESW counterclaimed damages caused by the lessor. On August 4, 2005, Elron paid the lessor \$950 in full and final settlement and release of all the above claims, pursuant to a settlement agreement signed between the parties in July 2005. The settlement agreement has no effect on the statement of operations.

NOTE 5:- INCOME TAXES

On July 25, 2005, the Israeli parliament approved the Law for the Amendment of the Income Tax Ordinance (No. 147), 2005 which progressively reduces the corporate tax rate in Israel to the following tax rates: in 2006 - 31%, in 2007 - 29%, in 2008 - 27%, in 2009 - 26% and in 2010 and thereafter - 25%. The amendment is not expected to have a material effect on the Company's financial position and results of operations.

NOTE 6:- BUSINESS SEGMENTS

As of June 30, 2005, the Company operates in two business segments: (1) the System and Projects segment through the ET group and (2) the Other Holdings and Corporate Operations segment which reflects the investments in companies engaged in various fields of advanced technology and also includes corporate headquarters.

The operations of the System and Projects segment include development and supply of software solutions for revenue assurance and management of large and complex communication and internet networks.

The Other Holdings and Corporate Operations segment includes holdings in various companies that operate in the telecom, medical devices, semiconductors, advanced materials and other fields and the corporate operations.

On September 2, 2003, Elron's majority owned subsidiary, ESW, sold substantially all of its assets and business to Zix (See Note 3d to the Company's annual financial statements). Prior to the above sale, the Company operated indirectly through ESW in a third business segment - Internet Products.

Segment information is as follows:

	Systems and Projects	c	Other holdings and corporate perations	Internet Products (Discontinued operations)		Adjustments			Total
For the six months ended June 30, 2005 (Unaudited): Net revenues Net income (loss)	\$ 2,272 (2,075)	\$	6,246 44,162	\$		\$	<u>-</u> -	\$	8,518 42,087
As of June 30, 2005 (Unaudited): Total assets	5,165		467,685		-		(2,408) (*)		470,442

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 6:- BUSINESS SEGMENTS (Cont.)

		Systems and Projects		and		and		Other holdings and corporate operations		Internet Products (Discontinued operations)		Products (Discontinued		ljustments	Total
For the six months ended June 30, 2004 (Unaudited):															
Net revenues Net income (loss)	\$	3,440 (1,108)	\$	3,561 10,665	\$	(356)	\$	- -	\$ 7,001 9,201						
For the three months ended June 30, 2005 (Unaudited):															
Net revenues Net income (loss)	\$	999 (1,599)	\$	3,261 48,799	\$	-	\$	- -	\$ 4,260 47,200						
For the three months ended June 30, 2004 (Unaudited):															
Net revenues Net income (loss)	\$	1,784 (551)	\$	1,792 6,086	\$	(56)	\$	-	\$ 3,576 5,479						
For the year ended December 31, 2004 (Audited):															
Net revenues Net income (loss)	\$	5,065 (7,946)	\$	11,265 92,533	\$	- (454)	\$	- -	\$ 16,330 84,133						
As of December 31, 2004 (Audited):															
Total assets		7,630		495,642		-		(2,116)(*)	501,156						

^(*) Inter-company balances.

NOTE 7:- RECONCILIATION TO ISRAELI GAAP

The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP. Had the consolidated financial statements been prepared in accordance with Israeli GAAP, the effects on the financial statements would have been as follows:

a. Effect on the statement of operations:

	Six months ended June 30, 2005											
A	s reported				per Israeli GAAP							
\$	42,087	\$	18,217	\$	60,304							
	Six n	e 30, 2004										
<u>r</u>	As eported(*)				per Israeli GAAP							
<u> </u>	0.201			C	8,197							
	\$	As reported \$ 42,087 Six n As reported(*)	As reported Ad \$ 42,087 \$ Six months As reported(*) Ad	As reported Adjustments Unaudited \$ 42,087 \$ 18,217 Six months ended June As reported(*) Adjustments Unaudited	As reported Adjustments Unaudited \$ 42,087 \$ 18,217 \$ Six months ended June 30, 200 As As reported(*) Adjustments Unaudited							

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

b.

NOTE 7:- RECONCILIATION TO ISRAELI GAAP (Cont.)

a. Effect on the statement of operations (Cont.)

		Three	mont	hs ended Jun	e 30, 2	005
	Δ.	s reported	Δ.	djustments	As	per Israeli GAAP
	A	s reported		Unaudited	-	GAAI
Net income	\$	47,200	\$	20,789	\$	67,989
		Three	mont	hs ended Jun	e 30, 2	2004
		As		1	As	per Israeli
	re	eported(*)	A	djustments Unaudited	-	GAAP
Net income	\$	5,479	\$	(2,689)	\$	2,790
				Year ended ember 31, 200	04	
				1	As	per Israeli
	_A	s reported	A	djustments Audited		GAAP
Net income	\$	84,133	\$	7,896	\$	92,029
Effect on the balance sheet:						
Effect on the surance sheet.						
Effect on the building sheet.			J	une 30, 2005		
Sheet on the statutes sheet.	A	s reported			As	per Israeli GAAP
Sheet on the statutes sheet.	A	s reported_		une 30, 2005 djustments Unaudited	As	_
Total assets	A	s reported 470,442		djustments	As	_
			A	djustments Unaudited		GAAP
Total assets Total liabilities including minority		470,442	A	djustments Unaudited (69,432)		401,010
Total assets Total liabilities including minority interest		470,442 88,873	A (djustments Unaudited (69,432) (23,772)	\$	401,010 65,101
Total assets Total liabilities including minority interest	\$	470,442 88,873 381,569	\$ Dec	djustments Unaudited (69,432) (23,772) (45,660) ember 31, 200	\$	401,010 65,101 335,909
Total assets Total liabilities including minority interest	\$	470,442 88,873	\$ Dec	djustments Unaudited (69,432) (23,772) (45,660)	\$	401,010 65,101 335,909
Total assets Total liabilities including minority interest	\$	470,442 88,873 381,569	\$ Dec	djustments Unaudited (69,432) (23,772) (45,660) ember 31, 200	\$	401,010 65,101 335,909
Total assets Total liabilities including minority interest Total equity	\$ A	470,442 88,873 381,569 s reported	\$ Dec	djustments Unaudited (69,432) (23,772) (45,660) ember 31, 200 djustments Audited	\$ 04 As	401,010 65,101 335,909 s per Israeli GAAP

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 7:- RECONCILIATION TO ISRAELI GAAP (Cont.)

c. Material adjustments:

The abovementioned adjustments result primarily from the differences between U.S. GAAP and Israeli GAAP as detailed in Note 29 to the Company's annual financial statements, as well as from transactions and events which occurred during the six and three months periods ended June 30, 2005, as follows:

- 1. As described in Note 3a above, Elbit sold in the second quarter of 2005 12,765,190 shares of Partner. According to Israeli GAAP, the merger between Elron and Elbit which occurred in May 2002, was considered to be a transaction with controlling shareholders and therefore the assets and liabilities of Elbit were recorded by Elron according to their carrying values in Elbit at the date of the merger (see Note 29(c)4 to the Company's annual financial statements). The carrying value of the Partner shares was approximately \$30 and therefore the gain after tax recorded in respect of the above sale of Partner shares under Israeli GAAP amounted to approximately \$61,700, as compared to approximately \$36,000 under US GAAP.
- 2. As described in Note 3e above, Elron sold all of its holdings in Oren in the second quarter of 2005. As a result of the difference between Israeli GAAP and US GAAP described in Note 29(c)2 to the Company's annual financial statements, Elron's investment in Oren at the date of sale under US GAAP was substantially lower than such investment under Israeli GAAP (the difference amounted to approximately \$5,000). As a result, the gain recorded under Israeli GAAP for the sale of the investment in Oren, amounted to approximately \$12,200, net of tax, compared to a gain, of approximately \$17,200, net of tax under US GAAP.

U.S. dollars in thousands

Details relating to major investments as of June 30, 2005:

	% of	Carrying value of the investment as of June 30,			tra investme	ded ents a	
	ownership interest ⁽¹⁾		une 30, 2005 ⁽²⁾		ne 30, 2005	August 8, 2005	
Consolidated Companies:							
Elron Telesoft Ltd. and Elron Telesoft Export Ltd.	1000/	¢.	2.661	¢.		Ф	
Galil Medical Ltd. ⁽³⁾	100% 40%	\$	2,661 1,218	\$	-	\$	-
3DV Systems Ltd. (3)	71%		(58)		_		_
Starling (3)	50%		648				
SELA (3)	39%				-		-
SELA	39%		1,348		-		-
Affiliated Companies (equity):							
Given Imaging Ltd. (Nasdaq: GIVN) (3)	20%		65,474		124,357		128,446
NetVision Ltd. (TASE: NTSN)	39%		3,975		18,098		20,389
ChipX	26%		3,269		-		-
CellAct Ltd.	45%		479		-		-
Oncura (4)	10%		11,449		=		-
AMT	41%		3,826		-		-
Wavion, Inc.	38%		573		-		-
Pulsicom Israel Technologies Ltd.	18%		229		-		-
Notal Vision, Inc.	26%		503		-		-
NuLens Ltd.	22%		1,276		-		-
Available for sale:							
Partner (Nasdaq: PTNR)	2%		22,134		22,134		25,133
EVS (Nasdaq: EVSNF.OB)	10%		1,295		1,819		2,163
Zoran (Nasdaq: ZRAN) (5)	1%		8,152		8,152		-
, , , , ,			-, -		-, -		
Partnership:							
Gemini Israel Fund L.P.	5%		37		-		-
InnoMed Ventures L.P.	14%		3,429		-		-
~ .							
Cost:	70/		2				
Avantry (formerly:Witcom Ltd.) (3) Jordan Valley	7% 28%		2 6,707		-		-
Impliant Inc.	28% 28%		6,707 7,340		-		-
Teledata Ltd.	21%		16,000		_		-
Torogana Eng.	21/0		10,000		_		_

⁽¹⁾ On the basis of the outstanding share capital.

⁽²⁾ Includes loans and convertible notes.

⁽³⁾ Represents the carrying value and the ownership interest of the investment in Elron's books and Elron's share in the carrying value and ownership interest of the investment in RDC's books.

⁽⁴⁾ Represents Elron's share in the carrying value and the ownership interest of the investment in Galil's books.

⁽⁵⁾ All shares were sold subsequent to the balance sheet date, in consideration for approximately \$ 8,800 (see Note 3e).